Summations
Cerebral vitamin D status may diverge from serum calcidiol levels
Cerebral vitamin D status may depend on pharmacogenetic characteristics
Treatment of CNS diseases with vitamin D may be indicated in only specific patient characteristics
Considerations
Only five papers of vitamin D and addiction were discovered searching PubMed and EMBASE
The impact of relevant pharmacogenotypes on CNS effects of calcitriol has hardly been studied
A well-designed trial of the efficacy of cholecalciferol in preventing depression had negative results
Introduction
Vitamin D belongs to a group of fat-soluble prohormones of the chemical subclass of steroids which include retinoic acid, sex hormones and adrenal steroids. Two clinically relevant forms of vitamin D exist, namely cholecalciferol (D3) and ergocalciferol (D2). Vitamin D2 is obtained from food, while the level of vitamin D3 depends on its synthesis from 7-dehydrocholesterol (a cholesterol derivative) within the skin under the influence of ultraviolet radiation (Webb et al., Reference Webb, Kline and Holick1988). In the liver, vitamin D3 is converted into the intermediate calcidiol (25-(OH)-D3) through hydroxylation by means of 25-hydroxylase. Calcidiol is, in turn, converted within the kidneys by 25OHD-1-α-hydroxylase (CYP27B1) into an active metabolite calcitriol (1,25-(OH) 2-D 3) (Fig. 1). Calcitriol is structurally related to the steroid hormones and it is not classified as a vitamin, but as a prohormone (Hollick, Reference Holick2002).
Simplified pathway for vitamin D biosynthesis and inactivation (Prosser and Jones, Reference Prosser and Jones2004). Cholecalciferol is synthetised within the skin. Calcitriol is the biologically active neurohormone which reacts with vitamin D receptor (VDR).
Metabolite calcidiol is the most important circulating form of vitamin D, but it has a low biological activity. In order to determine the value of vitamin D, it is considered sufficient to measure the calcidiol level in serum. It is, however, known that the active metabolite calcitriol has far higher affinity to the vitamin D receptor (VDR). VDR is involved in the regulation of more than 900 genes and a range of physiological processes (Kongsbak et al., Reference Kongsbak, Levring, Geisler and von Essen2013). VDR is present in cytoplasm and can be retrieved in vascular endothelial cells and the brain; pancreas; skin; cartilage; adrenals; mammary gland; muscle; liver, thyroid and immune cells (Pike and Meyer, Reference Pike and Meyer2010).
There are currently many hundreds of allelic variants of the VDR gene locus described and numerous studies have investigated the association of such variants (e.g. BsmI, FokI, TagI and ApaI) with the effect of vitamin D (Mukhtar et al., Reference Mukhtar, Sheikh, Suqaina, Batool, Fatima, Mehmood and Nazir2019). VDR gene polymorphisms can lead to a malfunction of calcitriol. In this way, it may limit vitamin D having an anti-inflammatory function by altering the calcitriol binding sites (Cieslinska et al., Reference Cieślińska, Kostyra, Fiedorowicz, Snarska, Kordulewska, Kiper and Savelkoul2018). VDR has also been found to upregulate the expression of the MDR1 gene encoding P-glycoprotein as well as that of CYP3A4 and, to a lesser extent, CYP2B6 and CYP2C9 genes (Drocourt et al., Reference Drocourt, Ourlin, Pascussi, Maurel and Vilarem2002; Chow et al., Reference Chow, Durk, Cummins and Pang2011).
As vitamin D deficiency and vitamin D receptor (VDR) gene polymorphisms have been linked to a wide range of diseases (e.g. inflammation, including various autoimmune diseases) (Altieri et al., Reference Altieri, Muscogiuri, Barrea, Mathieu, Vallone, Mascitelli, Bizzaro, Altieri, Tirabassi, Balercia, Savastano, Bizzaro, Ronchi, Colao, Pontecorvi and Della Casa2017; Martens et al., Reference Martens, Gysemans, Verstuyf and Mathieu2020), a causal relationship between various syndromes and the deactivation of VDR should obviously be considered. Deactivation of VDR is, however, far from the only mechanism how the effects of calcitriol can be affected. This can also be related to affecting calcitriol’s metabolism and transportation to sites of action.
A recent model for the mechanism of a set of essential mental symptoms defines two parallel circuits within the forebrain regulating the intensity of reward-seeking or distress-avoiding behaviour (Loonen and Ivanova, Reference Loonen and Ivanova2016, Reference Loonen and Ivanova2018; Loonen et al, Reference Loonen, Schellekens, Ivanova, Meil and Ruby2016). These circuits include the core and shell part of the nucleus accumbens, respectively. When the reward-seeking behaviour is successful, the individual experiences pleasure (hedonia) and when distress-avoiding behaviour is successful, feelings of happiness (euphoria) occur. The motivation to express these two types of behaviour depends on the activity of ascending monoaminergic neurons originating within the midbrain, more specifically the ventral tegmental area (dopamine, DA), the upper raphe nuclei (5-hydroxytryptamine, 5-HT) and the locus coeruleus (norepinephrine, NE). These ascending pathways are controlled by terminals originating within the habenuloid complex (Batalla et al., Reference Batalla, Homberg, Lipina, Sescousse, Luijten, Ivanova, Schellekens and Loonen2017). Dopaminergic neurons running to the core of the nucleus accumbens in particular are essential for substance use disorders but also have an important role in regulating psychomotor activity in depression, psychosis and mania. Dopaminergic neurons also run to the dorsal striatum and frontal and temporal lobes and are involved in a variety of neuropsychiatric symptoms concerning kinesis (Parkinson’s disease, Tourette syndrome); obsessions and compulsions (obsessive compulsive disorder); vigilance (attention deficiency hyperactivity disorder (ADHD)); anxiety; memory; hallucinations and delusions. The enzyme catechol-O-methyltransferase (COMT) metabolises DA and the COMT Val158Met single-nucleotide polymorphism (rs4680) significantly affects DA efficacy and tone within the prefrontal cortex (PFC), which moderates the effects of dopaminergic drugs on PFC-dependent cognitive functions (e.g., working memory, selective attention and executive function) (Schacht, Reference Schacht2016).
The aim of this study was originally to investigate whether vitamin D deficiency and/or VDR is pathophysiologically involved in the process of addiction and to review the clinical evidence justifying treatment of alcoholism and other forms of addiction with vitamin D. We hypothesised that the vitamin D status affects cerebral dopaminergic neurotransmission according to the schedule represented in Fig. 2. Unfortunately, this subject turned out to have hardly been investigated until now. We describe important considerations for the design of future research.
Possible influence of vitamin D on biosynthesis and inactivation of dopamine (Sibley et al., Reference Sibley, Hazelwood and Amara2018). AADC, aromatic L-amino acid decarboxylase; VDR, vitamin D receptor.
Systematic review
Identification
During a systematic search in December 2019 of the PubMed database of the National Library of Medicine as well as the EMBASE database published by Elsevier, we used the following keywords and syntaxis:
(vitamin d AND dopamine) OR (VDR AND dopamine) OR (VDR AND addiction) OR (vitamin d AND addiction) OR (vitamin d AND alcohol) OR (vitamin d AND stimulants) OR (VDR AND alcohol) OR (VDR AND stimulants) OR (vitamin d AND cocaine) OR (VDR AND cocaine)
Using this search strategy, we found 2293 titles in PubMed and 4151 titles in EMBASE. The number of review articles was 429 in PubMed and 1306 in EMBASE; the number of systematic reviews was 48 in PubMed and 25 in EMBASE. The number of randomised controlled trials was 67 in PubMed and 59 in EMBASE. Combining the search with genetic polymorphism gave 60 titles in PubMed and 78 titles in EMBASE.
By combining these searches, after considering the titles and selecting articles dealing with the central nervous system (CNS), neurological and/or mental disorders (more specifically addictive disorders) and after removing duplicates, we obtained a set of 178 studies, where two studies were listed twice, so ultimately in total 176 studies (Supplementary Table 1). After screening the summaries, some content duplicates and all irrelevant studies were removed (Table 1). As a result, we identified only five studies which specifically addressed the subject: one narrative review of animal data (Eserian, Reference Eserian2013); one systematic review (Tardelli et al., Reference Tardelli, Lago, Silveira and Fidalgo2017); one cross-sectional genetic association study (Wrzosek et al., Reference Wrzosek, Jakubczyk, Wrzosek, Kaleta, Łukaszkiewicz, Matsumoto, Brower, Nowicka and Wojnar2014) and two relevant clinical studies (Ghaderi et al., Reference Ghaderi, Banafshe, Motmaen, Rasouli-Azad, Bahmani and Asemi2017, Reference Ghaderi, Rasouli-Azad, Farhadi, Mirhosseini, Motmaen, Pishyareh, Omidi and Asemi2020) regarding the relationship of vitamin D with addiction (Table 2). Nevertheless, these studies were considered to be of interest for theory formation as is discussed below. In addition, we found 22 clinical studies on the influence of vitamin D in psychiatric disorders, including a comprehensive systematic review of the relationship between vitamin D and psychotic disorders (Adamson et al., Reference Adamson, Lally, Gaughran, Krivoy, Allen and Stubbs2017).
Number of studies covering the effects of vitamin D in combination with neurological and psychiatric illnesses and/or addiction
Studies of the effects of vitamin D in addiction
Description
In her narrative review of animal studies, Eserian (Reference Eserian2013) obtained support for the hypothesis that vitamin D would be an effective treatment approach for drug abuse and addiction. An important point may be that the administration of a single dose of vitamin D to new-born female rats resulted in augmentation of DA or its major metabolite in the brainstem, the hypothalamus and the striatum in adulthood (Tekes et al., Reference Tekes, Gyenge, Folyovich and Csaba2009a), indicating increased dopaminergic activity. The alterations were partly maintained transgenerationally in their (untreated) adult female offspring (Tekes et al., Reference Tekes, Gyenge, Hantos and Csaba2009b). Prenatal vitamin D deficiency delays or decreases the expression of genetic factors in rat embryos which are critical for the orderly development of DA neurons (Cui et al., Reference Cui, Pelekanos, Burne, McGrath and Eyles2010). This probably corresponds to the decreased neonatal expression of catechol-O-methyltransferase (COMT) gene of these ‘developmental vitamin D (DVD)-deficient’ rats (Kesby et al., Reference Kesby, Cui, O’Loan, McGrath, Burne and Eyles2010). After reaching adulthood, (especially female) DVD-deficient rats show an increased sensitivity to the behavioural effects of amphetamine as well as an increased expression of the dopamine transporter (DAT) protein, which is one of the targets of this drug. These findings clearly show that vitamin D deficiency has a long-lasting influence on the functioning of dopaminergic neurotransmission. The mechanism of these alterations are not yet known, but apart from being a potent inducer of endogenous glial cell line-derived neurotrophic factor (GDNF), calcitriol has also been found to increase the expression of tyrosine hydroxylase (TH) in vitro (Puchacz et al., Reference Puchacz, Stumpf, Stachowiak and Stachowiak1996). GDNF has a role in survival of adult dopaminergic neurons and in negatively regulating the actions of drugs of abuse (Carnicella and Ron, Reference Carnicella and Ron2009). Moreover, calcitriol has been reported to protect dopaminergic neurons against neurotoxicity by oxidative stress (Ibi et al., Reference Ibi, Sawada, Nakanishi, Kume, Katsuki, Kaneko, Shimohama and Akaike2001). In addition, vitamin D can increase glutathione levels and inhibit the expression of inducible nitric oxide synthase (iNOS) (Garcion et al., Reference Garcion, Sindji, Montero-Menei, Andre, Brachet and Darcy1998, Reference Garcion, Sindji, Leblondel, Brachet and Darcy1999), which both may result in strong antioxidant protection of dopaminergic neurons. It has been reported that vitamin D protects dopaminergic (and serotonergic) neurons against depletion by neurotoxic dosages of methamphetamine (Cass et al., Reference Cass, Smith and Peters2006). This neurotoxicity is associated with an increased expression of neuronal nitric oxide synthase (nNOS). It can be concluded that the pleiotropic effects of vitamin D observed in animal studies suggest its involvement of the functioning of dopaminergic neurotransmission.
Tardelli et al. (Reference Tardelli, Lago, Silveira and Fidalgo2017) systematically searched the literature in order to evaluate the association between ordinary alcohol use and vitamin D serum levels. Although, they identified 49 mainly cross-sectional (71.4%) studies of extensively varying size (from 10 to 14 641), they could not extract sufficient quantitative data to meta-analyse them. In almost all studies with a large patient number (>1000), a positive association (or no association) was found between regular alcohol use and vitamin D levels. These types of study are, however, not very helpful within the context of the present article, because the relationship may importantly differ in patients with alcohol use disorder from social drinkers: apart from a possible relationship with reward-seeking appetitive behaviour, this could also be related to liver damage or low exposure to sunlight.
Wrzosek and colleagues (Reference Wrzosek, Jakubczyk, Wrzosek, Kaleta, Łukaszkiewicz, Matsumoto, Brower, Nowicka and Wojnar2014) studied a possible association of FokI (rs2228570, T/C) single-nucleotide polymorphism of VDR gene, which is known to affect the VDR function. They included 148 patients (106 males and 42 females) with alcohol dependence according to DSM-IV criteria and 212 healthy controls. Their study may be statistically underpowered concerning the genetic difference between patients and controls, but they also measured impulsivity by applying the Barratt Impulsiveness Scale (BIS-11). In male patients, but not in females, (attentional) impulsivity according to BIS-11 scores was affected by their FokI VDR genotype. This might be related to an inability to drink alcohol in a controlled manner.
Ghaderi et al. (Reference Ghaderi, Banafshe, Motmaen, Rasouli-Azad, Bahmani and Asemi2017, Reference Ghaderi, Rasouli-Azad, Farhadi, Mirhosseini, Motmaen, Pishyareh, Omidi and Asemi2020) published the results of two randomised controlled trials of 50 000 IU of vitamin D or matching placebo taken every 2 weeks for 12 and 24 weeks, respectively. The level of blindness was not specified. They included only men, all of whom were receiving methadone maintenance treatment. They corrected for age and body mass index (BMI) by post-, respectively, pre-stratification. In their first study of 68 patients (verum = 34, placebo = 34), they concentrated on metabolic parameters, but as a primary outcome measured sleep quality and symptoms of depression and anxiety by administering specific questionnaires. Vitamin D significantly improved sleep quality and depressive symptoms, but anxiety scores did not alter (or only after post-stratification). Similar results concerning depression and anxiety scores were obtained in the second study of 64 different patients (verum = 32, placebo = 32). In this second study, the authors also measured cognitive function by administering a series of neuropsychological tests and found several significant differences between verum and placebo-treated patients.
Interpretation
The foregoing can be interpreted as that – although the evidence is weak – VDR might play a role in the pathophysiology of addiction. An essential aspect of addiction is the chance of relapse to abusing a specific substance when exposure occurs again after a period of abstinence. Additionally, at an earlier stage, specific sensory information (cues) lead to increased motivation to obtain alcohol or drugs. Both essential components of the ‘addiction process’ are directly linked to a hijacking and augmenting of the activity of reward-seeking forebrain circuits which include the core of the nucleus accumbens (Loonen and Ivanova, Reference Loonen and Ivanova2016, Reference Loonen and Ivanova2018; Loonen et al., Reference Loonen, Schellekens, Ivanova, Meil and Ruby2016). The addiction process is believed to exist from a three-stage cycle: binge/intoxication, withdrawal/negative affect and preoccupation/anticipation (Koob and Volkow, Reference Koob and Volkow2010). The second component of this cycle is probably related to a parallel activation of the distress-avoiding circuit, including the shell of the nucleus accumbens. The activity of these two circuits is regulated by the lateral and medial habenula, respectively, which affect the activity of ascending monoaminergic (DA, 5-HT and NE) pathways from the midbrain (Batalla et al., Reference Batalla, Homberg, Lipina, Sescousse, Luijten, Ivanova, Schellekens and Loonen2017). DA most extensively facilitates reward-seeking behaviour, and dopaminergic inactivity resulting from intoxication with DA-depleting substances results in relative overactivity of the distress-avoiding circuit leading to feelings of misery. This mechanism puts the protective activity of calcitriol against the neurotoxic effects of DA-depleting drugs in a more specific context (Cass et al., Reference Cass, Smith and Peters2006). Further, the association of a functional polymorphism of the VDR gene and impulsivity can be linked with the activity of ascending dopaminergic pathways to the (previously described) reward-seeking circuitry.
The biochemical mechanism which lies behind these activities is unclear. It has been suggested that vitamin D modulates GDNF, which has neuroprotective activity on dopaminergic neurons (Eserian, Reference Eserian2013), but vitamin D also has many other effects. Another neuronal mechanism might be that vitamin D regulates the activity of glutamatergic neurons projecting to the lateral habenula which inhibit the activity of ascending dopaminergic neurons. In addition, calcitriol could regulate the processing of DA, for example, by affecting the expression/or activity of DA transporters (DAT, vesicular monoamine transporter); enzymes (TH, monoamine oxidase, COMT) and/or DA receptors.
The role of vitamin D on the functioning of COMT in particular may be of interest within the context of this article. New-born DVD-deficient rats show decreased expression of COMT gene (Kesby et al., Reference Kesby, Cui, O’Loan, McGrath, Burne and Eyles2010). In an in vitro model, stimulation of overexpressed VDR resulted in elevated COMT gene expression (Pertile et al., Reference Pertile, Cui and Eyles2016). The activity of COMT may have an important influence on the functioning of the prefrontal cerebral cortex, which probably explains the association of the functional COMT Val158Met polymorphism with certain neuropsychiatric disorders such as ADHD (Taylor, Reference Taylor2018). This justifies a hypothesis which proposes that the functioning of the PFC may adequately reflect cerebral vitamin D status. The results of Wrzosek et al. (Reference Wrzosek, Jakubczyk, Wrzosek, Kaleta, Łukaszkiewicz, Matsumoto, Brower, Nowicka and Wojnar2014) and those of Ghaderi et al. (Reference Ghaderi, Banafshe, Motmaen, Rasouli-Azad, Bahmani and Asemi2017, Reference Ghaderi, Rasouli-Azad, Farhadi, Mirhosseini, Motmaen, Pishyareh, Omidi and Asemi2020) possibly also correspond to an effect within the prefrontal cerebral cortex.
A complication may be induced, both in studies and in daily practice, by the fact that patients are usually supplemented with cholecalciferol (vitamin D3), while the actual neurohormone is calcitriol (1,25-(OH)2-D3). Measuring total calcidiol (25-OH-D3) levels in serum is, up to now, considered to be a good indicator of vitamin D status. However, the described genetic variability decreases the reliability of this measure. In addition, polymorphisms of vitamin D binding protein (VDBP) gene may determine the free concentration and therefore penetration into the brain (Newton et al., Reference Newton, Baatz, Kindy, Gattoni-Celli, Shary, Hollis and Wagner2019), while the ratio between calcidiol and calcitriol may depend on genetic variants of enzymes which synthesise and metabolise calcitriol forms, respectively, CYP27B1 and CYP24A1. The role of vitamin D can only be made clear when we consider the influence of this genetic variability and for interpreting the result of treatment we need to correct the serum calcidiol level in order to obtain a better measure for the vitamin D status of the patient. Our hypothesis about the suspected effect of VDR follows the logical order as shown in Fig. 2.
Cases
In spite of the many uncertainties, we obtained some positive results in our clinical practice with the addition of vitamin D in the treatment of addicted patients. We started in one of them, a 49-year-old single male with a serious cocaine use disorder and moderate alcohol use disorder. (patient A), vitamin D supplementation with oral 25 000 IU cholecalciferol/1 ml ampoules; initially, 25 000 IU once weekly during 8 weeks and later switched to a dosage of 25 000 IU once per 2 weeks. In total, he received 15 ampoules. One month after starting supplementation with ampoules, he also took 800 IU cholecalciferol tablets daily, along with nalmefene against craving for alcohol, vitamin B complex twice daily and thiamine 50 mg twice daily. After a few months, his serum calcidiol had increased to 108 nmol/l (Table 3) and the patient felt considerably better; all depressive complaints had disappeared without a specific antidepressant drug treatment being taken. Another patient, a 40-year-old woman (patient D), sought help due to a severe tobacco use disorder with underlying unspecified ADHD/ADD problems. When admitted, she used 10 mg of methylphenidate up to 3–4 times daily and once daily 20 mg of citalopram in addition to nicotine patches for quitting smoking. Laboratory examination revealed a serum calcidiol level of 15 nmol/l and no other deviations. Based on these results, she was treated with oral dosage of 50 000 IU (as 1 ml = 25 000 IU ampoules) once weekly for 8 weeks. After 8 weeks, her calcidiol had increased to 70 nmol/l. In the meantime, she had stopped using methylphenidate and had started a tapering down schedule to stop citalopram.
Levels of vitamin D in four of our patients
Discussion
In both severely addicted patients, substantial mood problems responded quickly and well to treatment with relatively high dosages of cholecalciferol. Two other patients (B and C from Table 3) were treated with an oral dose of 1600 IE cholecalciferol (tablets) daily, but this treatment did not result in sufficiently high calcidiol levels (> 75 nmol/l) (Table 3). Apart from this dosage consideration, we expect that the response of every addicted patient may depend on the individual VDR polymorphisms in combination with polymorphisms in a variety of still to be determined other genes. As calcidiol has low activity and calcitriol is the true neurohormone, functional variants of CYP27B1 and CYP24A1 could also be relevant for treatment response (Olmoz-Ortiz et al., Reference Olmos-Ortiz, Avila, Durand-Carbajal and Diaz2015). Different countries adhere to varying calcidiol levels for defining vitamin D deficiency. A recent meta-analysis of 32 studies resulted in an appropriate lower limit of 30 ng/ml (75 nmol/l) (Garland et al, Reference Garland, Kim, Mohr, Gorham, Grant, Giovannucci, Baggerly, Hofflich, Ramsdell, Zeng and Heaney2014). For the time being this lower limit should be applied in our opinion, but the results of future pharmacogenetic studies could well make individualisation of the treatment goals feasible and advisable.
Required dosage in addiction
Various dosages of cholecalciferol are recommended for the treatment of different conditions (Pludowski et al., Reference Pludowski, Holick, Grant, Konstantynowicz, Mascarenhas, Haq, Povoroznyuk, Balatska, Barbosa, Karonova, Rudenka, Misiorowski, Zakharova, Rudenka, Łukaszkiewicz, Marcinowska-Suchowierska, Łaszcz, Abramowicz, Bhattoa and Wimalawansa2018). A regular daily vitamin D supplementation dosage of 3000–5000 IU is advised in general for the majority of disease-specific recommendations (Ekwaru et al., Reference Ekwaru, Zwicker, Holick, Giovannucci and Veugelers2014). However, this may be too low in certain CNS diseases. The negative results of a large placebo-controlled clinical trial on the prophylactic activity of daily 2000 IU cholecalciferol on depression or depressive symptoms are probably partly related to the relatively low dosage (Okereke et al., Reference Okereke, Reynolds, Mischoulon, Chang, Vyas, Cook, Weinberg, Bubes, Copeland, Friedenberg, Lee, Buring and Manson2020). Uncontrolled treatment with high dosages is on the other hand not desirable. In alternative medical (orthomolecular) practice, extremely high dosages (daily 1000 IU/kg body weight) are sometimes given (Tutor, Reference Tutor2019); these need all sorts of precautions to prevent adverse effects.
Usage of a biomarker for the cerebral vitamin D status might be a useful addition to this type of studies, especially when trying to find specific reasons for general treatment failure or for identifying factors contributing to specific secondary treatment effects (Ekwaru et al., Reference Ekwaru, Zwicker, Holick, Giovannucci and Veugelers2014).
Individualising the dosage
Correction for body weight (BMI) was encouraged by Ekwaru et al. (Reference Ekwaru, Zwicker, Holick, Giovannucci and Veugelers2014) who recommend vitamin D supplementation be 2 to 3 times higher for obese subjects and 1.5 times higher for overweight subjects relative to normal-weight subjects. In our opinion, it is more rational to consider BMI in combination with relevant gene polymorphisms which cannot be corrected for by measuring serum calcidiol levels.
Another possibility would be to measure the active form of vitamin D, calcitriol (1,25-(OH)2-D3), directly, but calcitriol serum levels may not adequately reflect vitamin D reserves due to its relative short and varying half-life and its dependence upon the activity of parathyroid hormone (Souberbielle et al., Reference Souberbielle, Cavalier, Delanaye, Massart, Brailly-Tabard, Cormier, Borderie, Benachi and Chanson2015). Nevertheless, some authors from North America and Brazil advise the measurement of both calcitriol and calcidiol, because in the case of inflammation the serum calcitriol levels can be much higher than that of calcidiol (Blaney et al., Reference Blaney, Albert and Proal2009). Calcitriol indeed plays an important role in the inflammatory process, but native TH is also present in some tissues in the body to form the active form of calcitriol without increasing its concentration in the general blood stream (Shah et al., Reference Shah, DiMartino, Trujillo and Kew2006). Moreover, the calcitriol brain/serum ratio is possibly variable, which would limit the value of measuring calcitriol serum levels in diseases of the CNS including addiction.
Many environmental circumstances may affect the vitamin D status of patients with alcohol and/or substance use disorders as well. Heavy smoking is an often-encountered complication in this patient group. Tobacco smoking has a significant effect on calcium and vitamin D metabolism (Brot et al., Reference Brot, Jørgensen and Sørensen1999), which may be partly related to its potency to induce CYP enzymes. In addition, excessive coffee intake (which is common in psychiatric patients in general as well) may be relevant because caffeine inhibits VDR expression and calcitriol-related effect in human osteoblasts in vitro (Rapuri et al., Reference Rapuri, Gallagher and Nawaz2007). Apart from the mentioned genetic variables, therefore, these and many other factors may affect the vitamin D status of patients with alcohol and/or substance use disorder.
Conclusion
From the foregoing, we can conclude that although measuring serum calcidiol levels should be recommended in patients with an alcohol/substance use disorder, serum calcidiol levels may not represent the actual cerebral vitamin D status. This may especially be true in patients with a polymorphism of VDR or other contributing genes such as COMT, VDBP, CYP27B1 and CYP24A1. For the time being treatment of patients with seriously lowered calcidiol levels with a high-dosage regimen of cholecalciferol (ampoules) aiming at calcidiol serum levels above 75 nmol/l is, at least, often indicated. However, experimental studies addressing the relationship between serum calcidiol levels and cerebral vitamin D status deserve high priority and may be relevant for several CNS disorders. Animal studies would best precede clinical pharmacological experimentation so as to obtain suitable clues for potential contributing factors. In order to determine which supplementary dosages of cholecalciferol is adequate in patients with addiction, a clinical parameter reflecting the cerebral vitamin D status should be included. Measuring the activity of the frontal cerebral cortex by means of a neuropsychological test battery reflecting COMT activity might be suitable to assess the cerebral vitamin D status in this type of pharmacogenetic research (cf. Ehlis et al., Reference Ehlis, Reif, Herrmann, Lesch and Fallgatter2007; Ghaderi et al., Reference Ghaderi, Rasouli-Azad, Farhadi, Mirhosseini, Motmaen, Pishyareh, Omidi and Asemi2020). Once the relationship with serum calcidiol levels and relevant genotypes is established, corrected calcidiol levels could be applied for therapeutic monitoring.
Supplementary material
To view supplementary material for this article, please visit https://doi.org/10.1017/neu.2020.41
Acknowledgements
The authors greatly appreciate the help of Mrs. Kate Barker (BA, PGCE) who has proofread the manuscript. The authors thank Prof. Dr. Frits A.J. Muskiet (University Medical Centre Groningen (UMCG), University of Groningen, the Netherlands), Dr. Jos Wielders (Meander Medisch Centrum, Amersfoort, the Netherlands), Dr. Glen J.H. Dumont (Amsterdam University Medical Center, the Netherlands) for contributing to the process of writing this article.
Conflict of interests
The authors report no conflicts of interest.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Open access
